key: cord-0747775-7y4krvv5 authors: Tsai, Keng-Chang; Huang, Yi-Chia; Liaw, Chia-Ching; Tsai, Chia-I; Chiou, Chun-Tang; Lin, Chien-Jung; Wei, Wen-Chi; Lin, Sunny Jui-Shan; Tseng, Yu-Hwei; Yeh, Kuo-Ming; Lin, Yi-Ling; Jan, Jia-Tsrong; Liang, Jian-Jong; Liao, Chun-Che; Chiou, Wen-Fei; Kuo, Yao-Haur; Lee, Shen-Ming; Lee, Ming-Yung; Su, Yi-Chang title: A traditional Chinese medicine formula NRICM101 to target COVID-19 through multiple pathways: a bedside-to-bench study date: 2020-11-19 journal: Biomed Pharmacother DOI: 10.1016/j.biopha.2020.111037 sha: a908c3826f887cc483396b769a7965227d59376a doc_id: 747775 cord_uid: 7y4krvv5 COVID-19 is a global pandemic, with over 50 million confirmed cases and 1.2 million deaths as of November 11, 2020. No therapies or vaccines so far are recommended to treat or prevent the new coronavirus. A novel traditional Chinese medicine formula, Taiwan Chingguan Yihau (NRICM101), has been administered to patients with COVID-19 in Taiwan since April 2020. Its clinical outcomes and pharmacology have been evaluated. Among 33 patients with confirmed COVID-19 admitted in two medical centers, those (n = 12) who were older, sicker, with more co-existing conditions and showing no improvement after 21 days of hospitalization were given NRICM101. They achieved 3 consecutive negative results within a median of 9 days and reported no adverse events. Pharmacological assays demonstrated the effects of the formula in inhibiting the spike protein/ACE2 interaction, 3CL protease activity, viral plaque formation, and production of cytokines interleukin (IL)-6 and tumor necrosis factor (TNF)-α. This bedside-to-bench study suggests that NRICM101 may disrupt disease progression through its antiviral and anti-inflammatory properties, offering promise as a multi-target agent for the prevention and treatment of COVID-19. In the eleventh month since the World Health Organization declared the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) outbreak a Public Health Emergency of International Concern, the virus has infected more than 50 million people and claimed 1.2 million lives. The global scientific community is speeding up to develop an effective treatment at an unprecedented pace [1, 2] . However, the efficacy of new therapeutics remains inconclusive [3] , and clinical trials of repurposed drugs such as hydroxychloroquine and lopinavir/ritonavir have been discontinued. In this context, adopting unconventional approaches is urgently needed. Compassionate use of unauthorized medicine [4] , real world study, and traditional medicine may offer unique insights to inform scientific studies and empirical research in order to solve the global crisis with grave health, economic and social impacts. Taiwan reported its first case of coronavirus disease 2019 (COVID-19) on January 21, 2020. Its proactive public health measures and robust healthcare system contributed to a relatively small caseload [5] . Treatments were predominantly symptomatic, and the use of hydroxychloroquine resulted in some patients experiencing palpitation or cardiac arrhythmias with persistent high fever. In medical centers designated to respond to COVID-19, some patients who remained in isolation wards without improvement were administered Taiwan Chingguan Yihau (NRICM101), a traditional Chinese medicine (TCM) formula prescribed and prepared by the in-house TCM departments. The plant-based formula targeting viral respiratory infection and immunomodulation was suggested by the National Research Institute of Chinese Medicine (NRICM) after evaluating clinical symptoms, herbs with corresponding indications, and prior experience during 2003 SARS outbreak [6, 7] . TCM practitioners in Taiwan's national health system were entitled to administer and dispense the J o u r n a l P r e -p r o o f medication as the practice of TCM pharmacy is integrated with that of traditional medicine. Clinical outcomes were promising but limited by a small sample size and lack of comparator arms. Inhibitory assays were therefore performed to confirm the interaction of the formula with viral proteins and other structures according to identified pathogenic pathways ( fig. 1) , i.e. the binding of viral spike protein to human angiotensin-converting enzyme 2 (ACE2), which provides the virus with access to invade host cells and replicate [8, 9] ; 3CL protease, a key enzyme in SARS-CoV-2 that cleaves the viral polypeptides to form functional proteins for SARS-CoV-2 replication [10] ; pro-inflammatory cytokines interleukin (IL)-6 and tumor necrosis factor (TNF)-α associated with fatal immune inflammatory response [11] [12] [13] [14] . In this bed-to-bench study we first present the real word evidence in clinical settings, followed by results of pharmacological assays showing viral plague formation, spike protein/ACE2 interaction, 3CL protease activity, and production of cytokines. Lastly, the formula and all the constituent herbs have been high performance liquid chromatography (HPLC) fingerprinted to ensure authentication and standardization. The research timeline and design is presented in Figure 2 . We conducted clinical, pharmacological, as well as standardization and quality control studies to evaluate the effectiveness of NRICM101. Approval of the human subject research was obtained from the institutional review boards of two medical centers (TSGHIRB No. C202005067 & TCVGH-IRB No. CE20193A). Informed consent was obtained from each patient. Patient information was anonymized and de-identified prior to analysis. J o u r n a l P r e -p r o o f Tri-Service General Hospital and Taichung Veterans General Hospital were among the 52 response and isolation hospitals designated by Taiwan Centers for Disease Control for treatment of severe COVID-19 cases. Thirty-five patients were admitted to the two medical centers between January and April, 2020. They received symptomatic treatment and/or hydroxychloroquine until 13 of them shifted to NRICM101 on a voluntary basis and with consent from the care teams. NRICM101 was administered three times daily, each time 100 mL 30 minutes after a meal until discharge. In Taiwan, the discharge criteria during the research period was 3 consecutive negative results for SARS-CoV-2 of respiratory tract samples, with each sample collected at least 24 hours apart (3N). Adverse events, if any, would be recorded on a standard form. The bedside study retrospectively examined demographic and clinical data of all the 35 patients. We used descriptive statistics to summarize our sample data by NRICM101 and non-NRICM101 groups. After excluding 2 cases (one received TCM intermittently and the other received intravenous immunoglobulin therapy), there were 12 in the NRICM101 group and 21 in the non-NRICM101 group. Distribution of age, gender, disease severity, comorbidity, length of hospital stay before 3N of the 2 groups is presented. The decoction of NRICM101 was prepared by the TCM pharmacies in the two medical centers, after slightly modifying the formula for mild cases included in the and simmered for the decoction to reduce to 300 mL. Herbal materials (10 items) were obtained from local licensed herbal stores and the TCM pharmacy of Tri-Service General Hospital. Each of them (1.0 g) was extracted with water (30 mL) at 100 ℃ for 1 hour and centrifuged at 1000 rpm for 10 minutes. The supernatant of all samples was further filtered through a 0.22 m of PTFE filter. All the samples were stored at -80 ℃ before HPLC analysis. Twelve batches of The standard solution of the major compound, baicalin (Sigma-Aldrich, 95%) was prepared in the DMSO, at the concentration of 10 mg/mL. The stock solution with 50% ACN in D.D. H2O was diluted to obtain the developing solutions, including seven concentrations in the range of 0.015-1.0 mg/mL. The worked solutions were filtered through a 0.22 µm filter before HPLC injection. Linear regression analysis was applied to achieve linearity by the integrated peak and the concentration at seven different worked concentrations. The analysis condition of HPLC was the same with those of the NRICM101 decoction. The ACE2-spike protein inhibition ELISA was carried out to determine the ability of NRICM101 to block the interaction between ACE2 and SARS-CoV-2 spike receptor-binding domain (RBD) protein (Sino Biological). In brief, microplate wells were coated with spike RBD protein (0.2 µg/well). After blocking with 1% bovine serum albumin (BSA), plates were washed with phosphate-buffered saline with Tween detergent (PBST). Then, 5-, 10-, 20-, 40-, 80-, 160-, 320-, 640-, 1280-, 2560-, 5120-J o u r n a l P r e -p r o o f fold diluted samples were added to the wells to react with spike RBD protein. After washing with PBST, ACE2 protein (0.2 μg/mL, Sino Biological) was added to each well for incubation. Next, a rabbit anti-His tag antibody conjugated with horseradish peroxidase (HRP) was used (Immunology consultants laboratory, Inc.) for detection. Finally, each well was given the 3,3',5,5' tetramethylbenzidine (TMB, SeraCare) for color development. After stopping the reaction with 1N HCl, signal intensity was then measured at OD 450 nm (SPECTROstar Nano, BMG LABTECH). Binding reactivity to spike RBD protein of SARS-CoV-2 was performed by SPR (OpenSPR, Nicoyalife). The recombinant spike RBD protein was diluted to 25µg/mL with PBS and captured by a NTA chip (Nicoyalife). The analytes were tested in different dilutions in PBS and maintained the flow rate at 20 µL/min to analyze. The NTA sensor chip was regenerated with 10 mM glycine-HCl, pH2.2 (Nicoyalife). The results were analyzed using TraceDrawer software (Nicoyalife). The assay, modified from previous research [15] , was performed with a volume of Using varying levels of NRICM101 dilution as analytes in the surface plasmon resonance (SPR) analysis, the binding affinity of NRICM101 for RBD protein was found to be dose-dependent ( fig. 3A ). In the ACE2-spike protein inhibition enzyme- In the cytokine inhibition assays, each of the 10 herbs were individually analyzed. The extracts of HC and HA with 20-fold dilutions were able to inhibit TNF-α production at a rate greater than 50%. HA continued to inhibit production of TNF-α and IL-6 in a 40-fold dilution, suggesting that HA could be the major contributor to NRICM101 activity ( fig. 4E,F) . Finally, HPLC fingerprint analyses of NRICM101 and its 10 constituent herbs were conducted for quality control and the isolation and identification of lead compounds. Seventeen compounds, including three caffeoylquinic acids (CQA), 3- The research demonstrates both antiviral and anti-inflammatory effects of NRICM101 to fight against COVID-19. Informative clinical data shows that patients isolated for 21.5 days without signs of improvement achieved 3N 9 days after shifting to NRICM101, with no adverse events. In confirmative assays, NRICM101 exhibited antiviral effects by reducing spike protein's binding affinity, 3CL protease activities, and viral growth; it also appeared to suppress expression of IL-6 and TNF-α in alveolar macrophages. Disease severity, comorbidity and older age are identified risk factors of COVID-19 [17, 18] . In our study, patients who were older, sicker and having co-existing conditions concentrated in the NRICM101 group. They were the ones who did not achieve 3N throughout the 21 days of hospitalization and might have progressed to a Emerging evidence has demonstrated that IL-6 plays a crucial role in the pathophysiology of cytokine-driven fatal immune inflammatory response known as J o u r n a l P r e -p r o o f cytokine storm [29] . As cytokine storm is involved in the pathogenesis of severe COVID-19, therapeutics with the potential to mitigate IL-6 and TNF-α may attenuate disease progression and subsequent mortality [30] [31] [32] . In addition, in patients with severe COVID-19, a large number of pro-inflammatory monocyte-derived macrophages were found in bronchoalveolar lavage fluid [29] . Our result showed that NRICM101 and its component herb Scutellaria Root (HA) significantly suppressed the secretion of IL-6 and TNF-α in murine alveolar macrophages implying that NRICM101 has the potential to prevent COVID-19-induced cytokine storm. Baicalin, a main component in NRICM101 and in HA, has been reported to inhibit pulmonary inflammatory cytokines including IL-6, IFN-and TNF-and decrease the ratios of Th1/Th2 and Th17/Treg. Baicalin exhibits this capability via downregulation of RLRs signaling pathway, and thus controlling influenza A virus infection and improving the prognosis [33] . It has also demonstrated protection from polymicrobial sepsis via suppressing inflammatory response and lymphocyte apoptosis [34] . In brief, it may be the main component of NRICM101 for its anti-inflammatory activities. Existing TCM-based formulations to treat COVID-19 patients include Lianhua Qingwen Capsule, Qingfei Paidu Decoction, Maxinshigan Tang, Huashi Baidu Decoction, Jinhua Qinggan Granules, Xuanfei Baidu Decoction, and so on. These formulations were reported to have anti-viral, anti-inflammatory and immunoregulatory effects [35, 36] . The only available treatment being scientifically studied at the time of writingappeared to shorten the time to symptom recovery but did not show difference in the rate of conversion to severe cases or viral assay findings between treatment and control groups [37] . Despite some common ingredients, NRICM101 differs from most of these formulations in avoiding use of Ephedra sinica which contains ephedra, Asarum sieboldii which contains aristolochic acids, and mineral gypsum. Ephedra sinica is often used in traditional Chinese medicine to 'clear J o u r n a l P r e -p r o o f heat' but ephedra use is found to have significant safety concern [38, 39] . Aristolochic acids are known toxins and products containing them have been banned or restricted in many countries [40] . Without including these materials, NRICM101 exerted beneficial effects clinically and in vitro while ensuring safety by selecting plant-based and safeto-use ingredients. Limitations of the study include the small sample size and limited evaluation of underlying mechanisms. As of May 31, 2020, Taiwan reported 442 positive cases, thus constraining our inferential analysis by a small sample size. Secondly, in the real world situation we were unable to administer TCM or randomize treatment/observation arms at the onset of admission. More investigation is needed to explore possible effects and underlying mechanisms of NRICM101, and determine the optimal composition of herbal ingredients to maximize the formula's effectiveness. While the ability of NRICM101 to avert disease development requires further validation, our experience in Taiwan presents a multi-targeting and potentially safe and efficacious new drug candidate. The antiviral and anti-inflammatory effects of NRICM101 demonstrated in the study indicate that it may be used to inhibit mechanisms of SARS-CoV-2 invasion and proliferation. The urgency to alleviate COVID-19 and its associated societal burden warrants the possible contribution of this formula tested with the unconventional bedto-bench approach. J o u r n a l P r e -p r o o f inhibited LPS-induced expression of IL-6 and TNF-α in murine alveolar macrophages. The data represented as mean ± SD from three independent experiments. 50% inhibition concentration (IC50) and 50% cytotoxic concentration (CC50) were calculated by Prism software. The red dots indicate 50% inhibition; the data represented as mean ± SD from three independent experiments. World Health Organization, Timeline of WHO's response to COVID-19 Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review World Health Organization, Global scientific community unites to track progress on COVID-19 R&D, identifies new research priorities and critical gaps Compassionate Use of Remdesivir for Patients with Severe Covid-19 Response to COVID-19 in Taiwan: Big Data Analytics, New Technology, and Proactive Testing An Evaluation of the Additive Effect of Natural Herbal Medicine on SARS or SARS-like Infectious Diseases in 2003: A Randomized, Double-blind, and Controlled Pilot Study The lesson of supplementary treatment with Chinese medicine on severe laboratory-confirmed SARS patients Neutralization of SARS-CoV-2 spike pseudotyped virus by recombinant ACE2-Ig Angiotensin-2 is a functional receptor for the SARS coronavirus Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved α-ketoamide inhibitors COVID-19: immunopathogenesis and Immunotherapeutics Tocilizumab treatment in COVID-19: A single center experience Interleukin-6 in COVID-19: A Systematic Review and Meta-Analysis Traditional Chinese medicine needs proper scrutiny Characterization of SARS main protease and inhibitor assay using a fluorogenic substrate Flavonoid-mediated inhibition of SARS coronavirus 3C-like protease expressed in Pichia pastoris Clinical course and risk factors for mortality of adult inpatients with COVID-19 in China: a retrospective cohort study Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study Lamiaceae): a review of its traditional uses, botany, phytochemistry, pharmacology and toxicology A current update on the phytopharmacological aspects of Houttuynia cordata Thunb Antiviral Activities of Mulberry (Morus alba) Juice and Seed against Influenza Viruses, Evidence-Based Complement Indole alkaloid sulfonic acids from an aqueous extract of Isatis indigotica roots and their antiviral activity Antiviral activities of Schizonepeta tenuifolia Briq. against enterovirus 71 in vitro and in vivo Anti-SARS-CoV-2 activities in vitro of Shuanghuanglian preparations and bioactive ingredients Inhibition of SARS-CoV 3CL protease by flavonoids Characteristics of flavonoids as potent MERS-CoV 3C-like protease inhibitors In-Silico approach for identification of effective and stable inhibitors for COVID-19 main protease (Mpro) from flavonoid based phytochemical constituents of Calendula officinalis IL-6 in inflammation, immunity, and disease Cytokine release syndrome in severe COVID-19: interleukin-6 receptor antagonist tocilizumab may be the key to reduce mortality Role of Interleukin-6 in Lung Complications in Patients With COVID-19: Therapeutic Implications Single-cell analysis of two severe COVID-19 patients reveals a monocyte-associated and tocilizumab-responding cytokine storm Baicalin Downregulates RLRs Signaling Pathway to Control Influenza A Virus Infection and Improve the Prognosis, Evidence-Based Complement Baicalin Improves Survival in a Murine Model of Polymicrobial Sepsis via Suppressing Inflammatory Response and Lymphocyte Apoptosis Traditional Chinese Medicine in the Treatment of Patients Infected with 2019-New Coronavirus (SARS-CoV-2): A Review and Perspective Potential Targets for Treatment of Coronavirus Disease 2019 (COVID-19): A Review of Qing-Fei-Pai-Du-Tang and Its Major Herbs Efficacy and safety of Lianhuaqingwen capsules, a repurposed Chinese herb Psychiatric Effects of Ephedra Use: An Analysis of Food and Drug Administration Reports of Adverse Events Scientific Opinion on safety evaluation of Ephedra species for use in food Systematic Overview of Aristolochic Acids: Nephrotoxicity, Carcinogenicity, and Underlying Mechanisms We thank the Metabolomics Core Facility of the Agricultural Biotechnology Research Center at Academia Sinica for technical support. Competing interests: None.